Home › Markets › Health Care › QGEN

Qiagen N.V. Common Shares (QGEN)

QGEN trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$45.44
+0.29% on the day
Market cap
$9.4B
Mid cap
Revenue · 2025
$2.1B
+5.7% on 2024
Net income · 2025
$424.9M
20.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerQGEN on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNetherlands
IPO year2026
SEC CIK0001015820
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inP7

Financials · 2025

LineValue
Revenue$2.1B
Net income$424.9M
Operating income$465.9M
Net margin20.3%
Operating margin22.3%
Revenue growth+5.7%
Cash$839.0M
Total assets$6.3B
P/E (computed)22.0×
P/S (computed)4.5×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FINAL PROSPECTUS SUPPLEMENT
424B52009-09-25
Latest annual report20-F2026-03-20
Latest quarterly / interim6-K2026-09-09

Source: SEC EDGAR submissions feed, 506 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.1%
1 month+7.7%
3 months+10.2%
Year to date+1.7%
1 year-3.1%
From 52-week high-17.8%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
KRYSKrystal Biotech Inc.$321.16-3.29%$9.5B
KYMRKymera Therapeutics Inc.$106.68-4.82%$8.9B
TWSTTwist Bioscience Corporation$151.33-0.35%$10.0B
RGENRepligen Corporation$175.42+1.69%$8.6B
IBRXImmunityBio Inc.$9.80-3.16%$10.4B
PCVXVaxcyte Inc.$66.80-5.45%$10.5B
TECHBio-Techne Corp$72.48-0.11%$11.4B
HALOHalozyme Therapeutics Inc.$109.62-1.31%$12.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier